Laman Utama4DX • ASX
add
4DMedical Ltd
Tutup sebelumnya
$0.28
Julat hari
$0.28 - $0.29
Julat tahun
$0.23 - $0.72
Permodalan pasaran
128.37J AUD
Bilangan Purata
948.52K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
ASX
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(AUD) | Dis 2024info | Perubahan T/T |
---|---|---|
Hasil | 1.45J | 265.33% |
Perbelanjaan pengendalian | 13.10J | 7.86% |
Pendapatan bersih | -9.58J | -22.82% |
Margin untung bersih | -662.04 | 66.38% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -11.23J | -1.87% |
Kadar cukai berkesan | -0.04% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(AUD) | Dis 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 15.95J | -66.68% |
Jumlah aset | 102.01J | -29.03% |
Jumlah liabiliti | 42.15J | -19.87% |
Jumlah ekuiti | 59.86J | — |
Syer tertunggak | 413.32J | — |
Harga kepada buku | 2.04 | — |
Pulangan pada aset | -28.80% | — |
Pulangan pada modal | -45.42% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(AUD) | Dis 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -9.58J | -22.82% |
Tunai daripada operasi | -7.07J | 4.01% |
Tunai daripada pelaburan | -422.55K | 97.85% |
Tunai daripada pembiayaan | 170.01K | -98.95% |
Perubahan bersih dalam tunai | -7.33J | 32.46% |
Aliran tunai bebas | -6.17J | 4.49% |
Perihal
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Diasaskan
2013
Tapak web
Pekerja
145